AndroGel Employer and ICHRA Coverage: How to Manage Your Benefits in 2026

What Is AndroGel and Why Coverage Matters

AndroGel delivers testosterone transdermally to men diagnosed with primary or secondary hypogonadism. The FDA approved the 1% formulation in 2000 and the higher-concentration 1.62% formulation in 2011, both specifically for confirmed low testosterone in adult males [1]. Hypogonadism affects an estimated 2.1% to 3.8% of adult men by laboratory criteria, though symptomatic prevalence is higher in older cohorts [2].

The Clinical Basis for Treatment

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy recommends treatment for men with "unequivocally low serum testosterone concentrations and symptoms or signs of hypogonadism" [3]. The guideline specifies a threshold of total testosterone below 300 ng/dL on two morning measurements as the standard diagnostic criterion before initiating any form of testosterone replacement, including topical gel.

Why the Price Gap Creates Real Problems

Without coverage, AndroGel 1.62% (a 30-day pump supply) lists between $400 and $550 at major retail pharmacies. That figure comes from FDA Orange Book pricing data and GoodRx market surveys updated through late 2025. Men who miss the formulary window, lack an ICHRA, or are unaware of assistance programs often discontinue therapy. Discontinuation of prescribed TRT is associated with return of hypogonadal symptoms, including fatigue, reduced lean mass, and worsened quality-of-life scores, as documented in a 2019 JAMA Internal Medicine analysis of testosterone prescribing patterns [4].

How Employer Health Plans Cover AndroGel

Most large-group employer plans place AndroGel on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), which carries a co-pay of $60 to $150 per fill or a 30% to 50% co-insurance requirement. Smaller self-funded plans vary widely. Here is what you need to know before your first fill.

Formulary Verification Steps

1. Log into your plan's online formulary tool or call the member services number on your insurance card.
2. Search by the brand name "AndroGel" and by the generic name "testosterone gel."
3. Confirm which tier applies and whether prior authorization (PA) is required.
4. Ask specifically whether the 1% or 1.62% concentration has a different tier, because some plans treat them separately.

Prior Authorization Requirements

PA is common for brand-name AndroGel when a generic testosterone gel is on the formulary. Your prescribing clinician must typically submit documentation of two fasting morning testosterone levels below 300 ng/dL, a diagnosis code of E29.1 (testicular hypofunction) or E23.0 (hypopituitarism), and a statement that the patient tried or is contraindicated for the generic formulation. The American Association of Clinical Endocrinology (AACE) 2022 guidelines note that testosterone gel formulations differ in alcohol base, pump calibration, and absorption variability, which can justify brand-specific prescribing in certain patients [5].

Step Therapy and Generic Substitution

Many PBMs (pharmacy benefit managers) require a trial of generic testosterone gel 1% before approving brand AndroGel 1.62%. Generic testosterone gel 1% has been available since 2015, following FDA approval of the first ANDA [6]. If your plan requires step therapy, your clinician can document a clinical rationale for bypass, such as skin sensitivity to the excipients in the generic or a documented inadequate response at equivalent doses.

ICHRA and AndroGel: A Detailed Walkthrough

An Individual Coverage Health Reimbursement Arrangement (ICHRA) is an employer-funded account that reimburses employees for individual health insurance premiums and, in some plan designs, qualifying out-of-pocket medical expenses, including prescription drugs. ICHRAs were established under a final rule issued by the Departments of Treasury, Labor, and Health and Human Services in June 2019, effective for plan years beginning January 1, 2020 [7].

What ICHRA Reimburses

Under the 2019 final rule, ICHRA funds can reimburse:

• Individual health insurance premiums (the most common use)
• Out-of-pocket costs for medical care and prescription drugs if the employer's ICHRA plan document permits "excepted benefit" or "integrated" coverage of expenses
• Premiums for Medicare Parts A, B, C, and D for eligible employees

AndroGel prescribed for diagnosed hypogonadism qualifies as a reimbursable medical expense under IRS Publication 502, which lists "prescription medicines or drugs" as deductible medical expenses [8]. An ICHRA that covers out-of-pocket drug costs can therefore reimburse the patient's co-pay, co-insurance, or even the full retail cost if the employee is purchasing a non-covered drug.

How to Submit an AndroGel Claim Through ICHRA

1. Obtain a written prescription from your clinician with the diagnosis code.
2. Keep the pharmacy receipt showing the drug name, quantity, date, and amount paid.
3. Submit the receipt to your ICHRA administrator (common platforms include PeopleKeep, Take Command Health, and Thatch).
4. Reimbursement typically processes within 3 to 7 business days after documentation approval.

ICHRA Contribution Limits in 2026

For 2026, the IRS has not yet finalized indexed ICHRA limits at the time of this writing, but the 2025 limit for excepted benefit HRAs (a related account type) was $2,150 per year. Employers set ICHRA amounts independently with no statutory cap on the employer contribution, though contributions must be uniform within the same employee class as defined by the 2019 final rule [7].

Using HSA and FSA Funds for AndroGel

AndroGel with a valid prescription is an HSA- and FSA-eligible expense under IRS Section 213(d). This applies to both brand-name and generic testosterone gel. The IRS defines qualified medical expenses to include amounts paid for "medicine or drugs" that require a prescription, confirmed in IRS Publication 502 [8].

HSA Contribution Limits for 2026

For 2026, the IRS set HSA contribution limits at $4,300 for self-only coverage and $8,550 for family coverage under a high-deductible health plan (HDHP), with a $1,000 catch-up contribution permitted for enrollees aged 55 and older [9]. A full year of AndroGel at $400 per month would total $4,800, meaning an HSA alone may not cover the full annual cost at retail price, which reinforces the value of combining HSA dollars with a manufacturer copay card or ICHRA reimbursement.

FSA Use and the Use-It-or-Lose-It Rule

Flexible spending accounts offer a use-it-or-lose-it feature, but the IRS permits employers to allow a $660 rollover in 2026 or a 2.5-month grace period. If you have AndroGel fills scheduled in December or early January, timing them to maximize FSA balance drawdown before forfeiture is a practical cost-management step.

Manufacturer Assistance: myAbbVie Assist

AbbVie operates the myAbbVie Assist patient assistance program, which provides AndroGel at no cost to eligible patients who are uninsured or underinsured and meet income criteria. As of 2025, eligibility generally requires a household income at or below 400% of the federal poverty level (FPL) for the uninsured pathway, though AbbVie updates these criteria periodically [10].

Commercial Copay Card

For commercially insured patients, AbbVie offers a savings card that may reduce the out-of-pocket cost to as low as $0 per month for eligible prescriptions, subject to a maximum annual savings cap. Government-insured patients (Medicare, Medicaid, TRICARE) are typically excluded by federal anti-kickback statute guidelines. The FDA has not restricted copay card use for AndroGel specifically, but payers may implement accumulator adjustment programs that prevent copay card spending from counting toward a patient's deductible [11].

Accumulator Adjustment Programs: A Hidden Cost

An accumulator adjustment program (AAP) is a PBM policy that excludes manufacturer copay card contributions from a patient's out-of-pocket accumulator. This means a patient may believe they have met their deductible, only to discover the plan did not credit the manufacturer's payments. A 2022 analysis in the American Journal of Managed Care estimated that AAPs affected approximately 18% of commercially insured patients using copay cards for brand-name drugs [12]. Ask your PBM or HR benefits administrator directly whether your plan uses an AAP before relying on a copay card as your primary savings strategy.

Generic Testosterone Gel: The Fastest Route to Lower Cost

Generic testosterone gel 1% is the single most reliable way to reduce AndroGel costs if you are not brand-dependent. At GoodRx prices current through late 2025, generic testosterone gel 1% (60 g, equivalent to a common 30-day supply) ranges from $40 to $90 at most major pharmacy chains with a discount code, compared with $400 or more for brand AndroGel.

Clinical Equivalence Data

The FDA requires generic testosterone gel to demonstrate bioequivalence to the reference listed drug. A pharmacokinetic bioequivalence study published in support of the first ANDA approval showed that generic testosterone gel 1% produced a 90% confidence interval for Cmax and AUC within the 80% to 125% bioequivalence standard required by FDA guidance [6]. Clinically, both formulations deliver testosterone through the same transdermal absorption mechanism, and the Endocrine Society's 2018 guideline does not preferentially recommend brand over generic for routine cases [3].

When Brand Is Clinically Justified

Some patients report application-site reactions to the alcohol or thickening agents used in generic formulations. AndroGel 1.62% uses a proprietary metered-dose pump that allows precise 20.25 mg per actuation dosing, which may benefit patients requiring fine-grained titration. Your clinician can document these factors to support a PA for brand-name therapy when generic substitution is not appropriate.

Telehealth and Cash-Pay TRT as a Cost Comparison

Telehealth TRT platforms often prescribe testosterone cypionate (injectable) or compounded testosterone gel as alternatives to brand AndroGel. Cash-pay injectable testosterone cypionate 200 mg/mL (10 mL vial) costs approximately $30 to $60 at retail pharmacies with a GoodRx coupon, making it substantially cheaper than any gel formulation. The tradeoff involves injection technique, more frequent dosing adjustments, and a different pharmacokinetic profile. A 2021 review in the Journal of Clinical Endocrinology and Metabolism noted that injectable testosterone produces higher peak-to-trough variability compared with daily topical application, which some patients and clinicians prefer to avoid [13].

Compounded testosterone gel from a 503B outsourcing facility falls outside FDA-approved labeling but may be reimbursed through FSA/HSA funds as a prescribed medication. The FDA does not prohibit compounded testosterone gel for individual patients with a valid prescription, though it does not appear on the FDA's approved drug list and carries no bioequivalence data [14].

Step-by-Step Coverage Optimization for 2026

The following sequence applies to most commercially insured patients seeking the lowest net cost for AndroGel or its therapeutic equivalents.

Step 1. Confirm Your Diagnosis Is Documented

Two fasting morning total testosterone measurements below 300 ng/dL, drawn on separate days, are the standard threshold per Endocrine Society guidelines [3]. Incomplete documentation is the most common reason PA requests are denied.

Step 2. Check the Formulary Before the Prescription Is Written

Ask your clinician to check your specific plan's formulary for both brand and generic testosterone gel. If generic testosterone gel 1% is Tier 1 or Tier 2, the net cost after co-pay is likely lower than any coupon program for the brand.

Step 3. Apply for the AbbVie Copay Card at the Same Time as the PA

AbbVie's online enrollment takes approximately 10 minutes. Print or save the card number before your first fill so the pharmacy can apply it immediately. Do not wait until after the first out-of-pocket fill to enroll, because most programs do not retroactively reimburse prior fills.

Step 4. Verify Whether Your Plan Uses an Accumulator Adjustment Program

Call the member services number and ask: "Does my plan use an accumulator adjustment program or a copay accumulator?" If yes, the copay card savings will not count toward your deductible. In that case, switching to generic or pursuing ICHRA reimbursement is the more predictable cost path.

Step 5. Submit Out-of-Pocket Costs to ICHRA or HSA

Keep every pharmacy receipt. Organize by date and fill number. ICHRA administrators and HSA custodians require itemized receipts, not just credit card statements.

Monitoring and Dose Titration After Starting Coverage

Starting AndroGel does not end the administrative work. Dose changes require new PA documentation in many plans. The Endocrine Society recommends measuring serum testosterone 14 days after initiating or changing a topical testosterone dose, targeting mid-normal range values of 400 to 700 ng/dL [3]. A dose increase from 40.5 mg/day to 81 mg/day (two pumps to four pumps of AndroGel 1.62%) may trigger a new PA review if the plan's authorization was written for a specific daily dose.

Hematocrit should be checked at baseline, at 3 months, and then annually per FDA labeling, because testosterone therapy increases erythropoiesis [1]. Prostate-specific antigen (PSA) monitoring is also required per the AndroGel prescribing information, with baseline and 3- to 6-month follow-up measurements in men over 40 [1]. These lab costs are separately billable and are generally covered under preventive or diagnostic benefit categories, but confirm with your plan.